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Abstract 
Background and Aim: The reduced expression in immortalized cells REIC/Dkk-3 
gene, tumor suppressor gene, is downregulated in various malignant tumors. In a 
prostate cancer study, an adenovirus vector carrying the REIC/Dkk-3 gene (Ad-REIC) 
induces apoptosis. In the current study, we examined the effects of REIC/Dkk-3 gene 
therapy in pancreatic cancer. 
Methods: REIC/Dkk-3 expression was assessed by immunoblotting and 
immunohistochemistry in the pancreatic cancer cell lines (ASPC1, MIAPaCa2, Panc1, 
BxPC3, SUIT-2, KLM1 and T3M4) and pancreatic cancer tissues. The Ad-REIC agent 
was used to investigate the apoptotic effect in vitro and anti-tumor effects in vivo. We 
also assessed the therapeutic effects of Ad-REIC therapy with gemcitabine. 
Results: The REIC/Dkk-3 expression was lost in the pancreatic cancer cell lines, and 
decreased in pancreatic cancer tissues. Ad-REIC induced apoptosis and inhibited cell 
growth in the ASPC1 and MIAPaCa2 lines in vitro, and Ad-REIC inhibited tumor 
growth in the mouse xenograft model using ASPC1 cells. The anti-tumor effect was 
further enhanced in combination with gemcitabine. This synergistic effect may be 
caused by the suppression of autophagy via the enhancement of mTOR signaling. 
Conclusions: Ad-REIC induces apoptosis and inhibits tumor growth in pancreatic 
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cancer cell lines. REIC/Dkk-3 gene therapy is an attractive therapeutic tool for 
pancreatic cancer.  
 
Key words: gene therapy, Dickkopf-related protein, apoptosis, mTOR pathway, 
autophagy 
 
Abbreviations: GEM, gemcitabine; ER, endoplasmic reticulum 
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Introduction 
Pancreatic cancer is a cancer with a poor prognosis and is the fourth largest cause of 
cancer death worldwide [1-3]. Currently, treatment with gemcitabine (GEM) is the 
standard therapy for unresectable pancreatic cancer. However, the overall 5-year 
survival rate of pancreatic cancer is less than 5% [4]. In order to achieve a breakthrough, 
various gene therapies for pancreatic cancer have been studied and applied in clinical 
applications [5-9].  
Reduced expression in immortalized cells (REIC), also known as the dickkopf 3 
(Dkk-3) gene, was originally identified to be a tumor suppressor gene in association 
with the immortalization of normal human fibroblasts and is downregulated in various 
cancers [10]. The REIC/Dkk-3 expression is lost or decreased in various cancers, while 
the overexpression of REIC/Dkk-3 caused by adenovirus vectors induces cancer cell 
death [11-16]. The overexpression of REIC/Dkk-3 induces endoplasmic reticulum (ER) 
stress evoked by unfolded proteins [13] that activate c-Jun N-terminal kinase (JNK) and 
stimulate apoptosis. Interestingly, apoptosis occurs in only cancer cells. Normal cells 
evade apoptosis and induce the immune response due to the induction of interleukin-7 
[17].  
In the current study, we evaluated the therapeutic potential of REIC/Dkk-3 gene 
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therapy to overcome the inferior prognosis observed in patients with pancreatic cancer.  
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Materials and Methods 
Cell lines and cell culture:  
The pancreatic cancer cell lines ASPC1, MIAPaCa2, Panc1 and BxPC3 were 
obtained from DS Pharma Biochemical Co., Ltd. (Osaka, Japan), SUIT-2 was obtained 
from the Japanese Collection of Research Bioresources (Tokyo, Japan) and KLM1 and 
T3M4 were obtained from the Riken cell bank (Ibaraki, Japan). ASPC1, MIAPaCa2 and 
Panc1 were maintained in Dulbecco’s modified Eagle’s medium DMEM (Invitrogen, 
Carlsbad, CA), BxPC3, SUIT2 and KLM1 were maintained in RPMI- 1640 (Sigma, St. 
Louis, MO) and T3M4 was maintained in F10-HAM (Sigma). The media were 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma), 1% 
non-essential amino acid (Sigma), 1% penicillin/streptomycin solution (Sigma) and 
amphotericin B (0.5 μg/ml). The cells were cultured at 37°C in a humidified atmosphere 
of 5% CO2 and 95% air and quiesced at subconfluence under restricted serum 
conditions with 0.1% dialyzed FBS for 24 hours before the experiment.  
 
Immunoblot analysis  
Cells were plated into six-well tissue culture plastic dishes and grown to confluence. 
The cells were washed twice with cold phosphate-buffered saline (PBS) and lysed with 
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PRO-PREP protein extraction solution (iNtRON Biotechnology, Gyeonggi, Korea). The 
samples were resolved via SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto Immobilon-PTM membranes (Millipore Corporation, Bedford, MA). The 
membranes were blocked with Tris buffered saline with Tween 20 (Sigma) (TBS-T) 
buffer containing 1% bovine serum albumin for one hour and then incubated with 
antibodies against human phospho-c-Jun (Ser73), human phospho-stress-activated 
protein kinase/Jun amino-terminal kinase (SAPK/JNK) (Thr183/Tyr185), 
phospho-mammalian target of rapamycin (p-mTOR) (Ser2448) (Ser2481), 
phospho-p70S6 kinase (p-p70S6K) (Thr389), human β-gal(LacZ), human β-actin (Cell 
Signaling Technology, Danvers, MA) and human phospho-inositol-requiring enzyme 
1α (IRE1α) (S724) (Abcam, Cambridge, MA).  
 
Pancreatic cancer tissues and immunohistochemistry 
Pancreatic cancer and adjacent tissues were obtained from 29 patients who underwent 
pancreaticoduodenectomy or distal pancreatectomy. None of the patients received 
chemotherapy before surgery.  
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. 
The sections were dewaxed and dehydrated. Following rehydration, the endogenous 
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peroxidase activity was blocked for 30 minutes in a methanol solution containing 0.3% 
hydrogen peroxide. Following antigen retrieval in citrate buffer, the sections were 
blocked overnight at 4°C and then probed with anti-human REIC/Dkk-3 antibodies [14]. 
The primary antibody was detected with a biotinylated anti-mouse antibody (Dako 
Japan, Tokyo, Japan). The signal was amplified via avidin-biotin complex formation 
and developed with diaminobenzidine followed by counterstaining with hematoxylin, 
dehydration in alcohol and xylene and mounting. The percentage of positively stained 
tumor cells per field was calculated and categorized into three groups: (-), 0-10% 
positive; (+), 10-30%; (++), 30-70%; and (+++), >70% in reference to a previous report 
[14]. All sections were examined and scored independently by two observers without 
any prior knowledge regarding clinical background. All discrepancies in the evaluation 
of the REIC/Dkk-3 expression were reviewed, and a consensus was reached.  
 
Adenovirus vectors 
REIC/Dkk-3 was overexpressed using an adenovirus [13]. A full-length cDNA was 
integrated into a cosmid vector pAxCAwt and transferred into an adenovirus vector 
according to the COS-TPC method (Takara Bio, Shiga, Japan). An adenovirus vector 
carrying the REIC/Dkk-3 gene (Ad-REIC) was created, and an adenovirus vector 
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carrying the LacZ gene (Ad-LacZ) was used as a control. A total of 2×105 cells/well 
were seeded in flat-bottomed six-well plates, incubated for 24 hours and treated with 
Ad-LacZ or Ad-REIC at the indicated multiplicities of infection (MOI) in serum-free 
medium for one hour. The medium was then changed to flesh complete medium. 
 
Assessment of cell proliferation and death 
A total of 2×105 cells/well were seeded in flat-bottomed six-well plates, incubated for 
24 hours and treated with Ad-LacZ or Ad-REIC at the indicated multiplicities of 
infection (MOI) in serum-free medium for one hour. The medium was then changed to 
flesh complete medium. After 24 hours of incubation, the cells were cultured for 72 
hours with or without 1 µM of gemcitabine (GEM) (Eli Lilly Co., Indianapolis, IN). 
Following the completion of the incubation period, Hoechst 33342 (Wako, Tokyo, 
Japan) was added to the medium at a concentration of 2 µg/ml, and the cells were 
incubated in the dark for 10 minutes [16]. The number of apoptotic cells was counted 
under a microscope, and the percentage for each sample was determined (100 cells were 
judged per field, and the average percentage of apoptotic cells in five different fields 
was calculated). Cell viability was measured by counting the number of viable cells. 
The cells were detached with trypsin, stained with 0.4% trypan blue and counted using 
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an automated cell counter (Life technologies Japan, Tokyo, Japan). 
 
Autophagy assay 
We used the Cyto-ID Autophagy Detection kit (Enzo Life Science, Inc., NY, USA) to 
evaluate the autophagy of pancreatic cancer cells infected with Ad-REIC. After 48 
hours of incubation, autophagy detection reagent and Hoechst33342 nuclear stain were 
added, and the results were evaluated using fluorescence microscopy. Rapamycin was 
used as an autophagy inducer. The cells were pretreated with 500 μM of rapamycin for 
12 hours. The number of cells exhibiting autophagy was counted under a fluorescence 
microscope, and the percentage for each sample was calculated (100 cells were judged 
per field, and the average percentage of cells exhibiting autophagy in five different 
fields was calculated). 
 
Pancreatic cancer xenografts in nude mice 
ASPC1 cells (2.0×106 in 100 μl of PBS) were injected subcutaneously into the left 
flanks of 8-week-old BALB/c nude mice (SLC, Hamamatsu, Japan). One week after 
injection, 1.0×109 plaque forming units of Ad-REIC or Ad-LacZ in 100 μl of PBS was 
injected intra and peritumorally. The same volume of PBS was injected as a negative 
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control. Starting two days after the injection of Ad-LacZ or Ad-REIC, the mice were 
treated weekly with the i.p. administration of GEM or PBS for four weeks. The dose of 
gemcitabine was 80 mg/kg administered weekly. The tumor size was measured every 
week for four weeks after injection. The tumor volume was calculated using the 
following empirical formula: V = 1/2 × [(the shortest diameter)2 × (the longest 
diameter)]. We assigned ten mice to each group. REIC/Dkk-3 protein expression was 
confirmed by the immunoblot analysis of the tumor tissues.  The mice were sacrificed 
after 72 h from the treatment with each adenovirus vector (Ad-LacZ, Ad-REIC). The 
proteins were extracted from the tumor tissues with snap-frozen in liquid nitrogen with 
PRO-PREP protein extraction solution. The care and treatment of the mice were in 
accordance with the guidelines of the IACUC at the Okayama University Faculty of 
Medicine. 
 
Statistical analysis 
Correlations between the REIC expression and clinicopathological variables were 
analyzed using the χ2 test. For the in vitro studies, each experiment was performed 
independently at least three times. Statistically significant differences were determined 
according to Student’s t-test using the JMP10 software program (SAS Institute, Japan). 
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Results 
REIC/Dkk-3 expression in pancreatic cancer 
In the ASPC1 cell line treated with Ad-REIC, a positive control, REIC/Dkk-3 
proteins were detected as major bands of 60 kDa in size. The REIC/Dkk-3 protein 
expression was assessed in several human pancreatic cancer cell lines (Fig. 1A). The 
REIC/Dkk-3 expression was absent in all pancreatic cancer cell lines (ASPC1, 
MIAPaCa2, Panc1, BxPC3, SUIT2, KLM1 and T3M4). REIC/Dkk-3 was detected in 
the normal pancreatic acinus, duct epithelial cells and cells in the islets of Langerhans; 
however, the expression of REIC/Dkk-3 was decreased in the cancer cells of the human 
pancreatic cancer tissues (Fig. 1B). Twenty-three cases (79.3%) exhibited a negative (-) 
signal for the REIC/Dkk-3 expression in the pancreatic cancer tissue. Four cases 
demonstrated a weak signal (+) for the REIC/Dkk-3 expression, while two cases 
displayed an intermediate signal (++). No cases showed a strong (+++) signal (Table 1). 
The REIC/Dkk-3 expression in the human pancreatic cancer cells tissues compared to 
that observed in the corresponding tumor-free sections. The islets of Langerhans, which 
are known to express REIC/Dkk-3 proteins [18], were used as a positive control. 
Seventeen cases (82.4%) showed a positive signal for the REIC/Dkk-3 expression in the 
tumor-free sections of the pancreatic tissue, while only three cases (17.6%) exhibited a 
15 
 
 
negative signal (Table 1).  
 
Cell proliferation and apoptosis 
As the REIC/Dkk-3 expression has been reported to induce apoptosis in prostate 
cancer cells [13], an MTT assay was performed to determine whether the REIC/Dkk-3 
expression influences cell growth in the pancreatic cancer cell lines ASPC1 and 
MIAPaCa2. Gemcitabine was also used to determine whether REIC gene therapy 
increases the effects of standard systemic chemotherapy against pancreatic cancer. The 
degree of cell proliferation was decreased in the Ad-REIC (300 MOI)-treated cells 
(ASPC1: 31.9±8.8%, MIAPaCa2: 39.7±11.6%, ratio to the Ad-LacZ-treated cells, 
p<0.05) and Ad-REIC (300 MOI) with GEM-treated cells (ASPC1:29.1±6.8%, 
MIAPaCa2:19.7±3.1％, ratio to the Ad-LacZ-treated cells, p<0.05) (Fig. 2A). The 
effects of REIC/Dkk-3 were assessed in order to investigate whether the elicited growth 
suppression was due to an increase in cell death. Hoechst 33342 staining demonstrated 
that the rate of apoptosis in the cells treated with Ad-REIC (ASPC1: 39.7 ± 7.0％, 
MIAPaCa2: 36.1 ± 5.7%) and Ad-REIC with GEM (ASPC1: 57.3 ± 8.5%, MIAPaCa2: 
56.1 ± 8.8%) was significantly higher than that of the cells treated with Ad-LacZ 
(ASPC1: 9.3 ± 0.7%, MIAPaCa2: 13.0 ± 1.4%) and Ad-LacZ with GEM (ASPC1: 23.0 
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± 3.5%, MIAPaCa2: 29.0 ± 5.3%) (Fig. 2B). 
 
Ad-REIC induced apoptosis via the c-Jun signaling pathway and suppressed 
autophagy 
We confirmed that the level of apoptosis achieved through the c-Jun N-terminal 
kinase (JNK) pathway was enhanced by Ad-REIC using an immunoblot analysis (Fig. 
3). This finding proves that REIC/Dkk-3 overexpression induces apoptosis by 
increasing ER stress in pancreatic cancer and other cancer cells [13-16]. In addition, the 
ER stress induced by Ad-REIC did not stimulate autophagy, but rather tended to 
suppress autophagy, although the difference was not statistically significant (Fig. 4). 
mTOR signaling, which is known to be a regulator of autophagy, was enhanced by 
Ad-REIC (Fig. 5).  
 
Mice xenograft models 
To determine whether Ad-REIC inhibits tumor growth in vivo, we constructed a 
mouse xenograft model using ASPC1 cells (Fig. 6A). Ad-REIC inhibited tumor growth 
by 76.4 ± 11.8%, while control Ad-LacZ did not exert any significant effects on tumor 
growth (108.9 ± 13.6%). Ad-REIC also inhibited tumor growth by 70.9 ± 14.8% 
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(p<0.05) under the presence of GEM. The tumor growth in the Ad-REIC group was 
significantly suppressed compared to that observed in the Ad-LacZ group (p<0.05).  
The efficiency of REIC/Dkk-3 gene transduction was shown with immunoblot 
analysis (Fig. 6B). The REIC/Dkk-3 protein was successfully expressed in the tumor 
tissues in Ad-REIC group and Ad-REIC+GEM group. 
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Discussion 
As the prognosis of patients with pancreatic cancer is poor [1-3], new therapies are 
needed to treat pancreatic cancer patients. Adenovirus-mediated gene therapy is a 
potential new method, and trials of this technique have been reported [19, 20]. In the 
current study, we assessed the possibility of Ad-REIC gene therapy for use in the 
treatment of pancreatic cancer.  
REIC/Dkk-3 has been reported to be an inhibitor of tumor growth in various cancers 
[21] [13-16] due to its actions in interfering with Wnt signaling [22]. Fong, D. et al. 
reported that the Dkk-3 expression is correlated with the prognosis of patients with 
pancreatic cancer and that Dkk-3 overexpression inhibits tumor growth in pancreatic 
cancer cell lines [23]. As these results suggested that Ad-REIC is a promising gene for 
use in therapy for pancreatic cancer, we assessed the expression of REIC/Dkk-3 in 
pancreatic cancer tissues and evaluated the therapeutic in vitro and in vivo effects using 
adenovirus vectors. The REIC/Dkk-3 expression was decreased or lost in the pancreatic 
cancer cell lines (Fig. 1A) and pancreatic cancer tissues (Fig. 1B). As expected, 
REIC/Dkk-3 overexpression induced apoptosis and inhibited cell proliferation (Fig 2).  
REIC/Dkk-3 overexpression induces apoptosis by increasing ER stress via the 
overproduction of REIC/Dkk-3 proteins in prostate cancer cells [13, 24]. In accordance 
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with the results observed for prostate cancer, in this study, the c-Jun N-terminal kinase 
pathway was activated by Ad-REIC in the pancreatic cancer cells (Fig. 3). These results 
suggest that Ad-REIC induces apoptosis by increasing ER stress in pancreatic cancer 
cells.  
We also examined the effects of Ad-REIC in combination with chemotherapy, as 
GEM is commonly used for standard chemotherapy in patients with pancreatic cancer 
[25]. Onimaru M. et al. reported that GEM synergistically enhances the effects of 
adenovirus gene therapy [26]. In the present study, GEM enhanced the anti-tumor 
effects of REIC/Dkk-3 in the pancreatic cancer tissues (Figs. 2 and 6). 
mTOR is known to be a strong suppressor of autophagy [27-29]. Autophagy is a 
catabolic membrane-trafficking process that is activated by various cellular stressors 
[30]. Autophagy has been reported to promote the survival of cancer cells and 
contribute to the development of tolerance to chemotherapy [30-32]. On the other hand, 
autophagy has been reported to suppress tumor growth [33, 34]. Although the effects of 
autophagy remain controversial, the inhibition of autophagy is believed to be beneficial 
for cancer therapy [35, 36]. ER stress has been reported to induce autophagy [37]; 
however, our results demonstrated that autophagy is not enhanced by Ad-REIC. In fact, 
treatment with Ad-REIC tended to suppress autophagy (Fig 4). This paradox is due to 
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the enhancement of mTOR signaling induced by Ad-REIC (Fig. 5). This mechanism of 
Ad-REIC may result in synergistic effects with chemotherapy and the ability to 
overcome drug resistance.  
As indicated above, Ad-REIC has the potential to improve treatments for 
drug-resistant pancreatic cancer by suppressing autophagy. Many patients cannot 
receive effective treatment because pancreatic tumors often acquire drug resistance. 
Ad-REIC therapy may provide such patients a ray of hope. 
In a prostate cancer study, REIC/Dkk-3 was reported to induce immunological effects 
that activate anti-tumor immune responses [38]. Although REIC/Dkk-3 has been 
reported to induce apoptosis via the c-Jun N-terminal kinase pathway in cancer cells 
[13], normal cells do not exhibit apoptosis due to the REIC/Dkk-3 expression. The 
REIC/Dkk-3 expression induces the production of interleukin (IL)-7 via the 
p38-STAT1-IRF-1 pathway [17, 39]. IL-7 is considered to stimulate systemic immune 
responses and exert anti-tumor effects. Such immune responses may lead to potential 
therapeutic effects on metastasis of pancreatic cancer. In the present study, we used 
immune-deficient mice that were not suitable for the study of anti-tumor immunity. As 
Ad-REIC is a promising gene therapy for pancreatic cancer patients, the development of 
a delivery method is important for the treatment of pancreatic cancer. Although it is 
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difficult to deliver viral gene therapy reagent to pancreatic cancer cells, endoscopic 
ultrasound (EUS)-guided approaches to treating pancreatic diseases have recently been 
generalized. EUS-guided approaches may be applied to new local therapeutic modalities 
[40]. 
 
Conclusion 
We demonstrated that REIC/Dkk-3 exerts anti-tumor effects in pancreatic cancer and 
other cancer cells. REIC/Dkk-3 gene therapy is a promising approach for overcoming 
pancreatic cancer. 
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Figure legends 
Figure 1. The REIC/Dkk-3 expression in the pancreatic cancer tissues.  
The REIC/Dkk-3 protein level was determined using an immunoblot analysis. The cell 
lysate obtained from the ASPC1 cells treated with Ad-REIC (20 MOI) was used as a 
positive control. Immunoblotting for β–actin was performed to verify equal loading. 
Representative blots of more than three independent experiments are shown (A). 
The pictures show the results of the REIC/Dkk-3 expression analysis of the human 
pancreatic tissue samples (top left: the islets of Langerhans in a tumor-free section 
scored (+++), top right: pancreatic cancer cells scored (-), bottom left: pancreatic cancer 
cells scored (+), bottom right: pancreatic cancer cells scored (++)). Representative 
pictures are shown. Scale bars, 50 μm (B). 
 
Figure 2. Effects of Ad-REIC in the pancreatic cancer cell lines. 
The degree of cell proliferation and apoptosis was evaluated using an MTT assay and 
Hoechst staining, respectively. An MTT assay was performed to determine whether 
Ad-REIC influences cell growth in the pancreatic cancer cell lines ASPC1 and 
MIAPaCa2. The concentrations of Ad-LacZ and Ad-REIC were diluted to 100 MOI and 
300 MOI. 1 mM of GEM was also used to determine whether REIC gene therapy 
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increases the effects of standard systemic chemotherapy against pancreatic cancer (A). 
Hoechst 33342 staining was performed to evaluate the degree of apoptosis. 
The results are presented as the mean ± SE (n=5) (B). 
 
Figure 3. Immunoblot analysis of the c-jun N-terminal kinase signaling pathway. 
An immunoblot analysis was performed to evaluate signals of the c-Jun N-terminal 
kinase pathway in Ad-REIC-transduced ASPC1 cells. The immunoblot analysis was 
performed using antibodies against IRE1, phospho-IRE1, phospho-JNK, phospho-c-Jun 
and β-actin. Immunoblotting for β-actin was performed to verify equal loading. 
Representative blots of more than three independent experiments are shown. 
 
Figure 4. Effects of Ad-REIC on autophagy. 
ASPC1 cells treated with Ad-LacZ and/or Ad-REIC in the presence of rapamycin (500 
μM). The cells were stained with autophagy detection reagent and Hoechst33342 and 
examined under fluorescence microscopy (A). The number of cells exhibiting 
autophagy was counted (B). 
 
Figure 5. Immunoblot analysis of the mTOR pathway. 
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An immunoblot analysis was performed to evaluate signals of the mTOR pathway in 
Ad-REIC-transduced ASPC1 cells. The immunoblot analysis was performed using 
antibodies against phospho-mTOR (s2448), phospho-mTOR (s2481), phospho-p70S6K 
and β-actin. Immunoblotting for β-actin was performed to verify equal loading. 
Representative blots of more than three independent experiments are shown. 
 
Figure 6. Effects of Ad-REIC on tumor growth in the mouse pancreatic cancer 
xenograft model. 
The inoculated mice were divided into five groups (control, Ad-REIC, Ad-LacZ, 
Ad-REIC+GEM and Ad-LacZ+GEM), and the tumor volume was measured as 
described in the Materials and Methods section. The data represent the mean ± SE of 
more than three independent experiments performed in ten mice (A). 
The immunoblot analysis was performed to evaluate the transduction efficiency of 
Ad-REIC in the tumor tissue. The tumor tissue samples were collected 72-h after the 
injection of Ad-REIC or Ad-LacZ. Immunoblot analysis was performed with 
anti-REIC/Dkk-3 antibody, anti-β-gal antibody, and anti-β-actin antibody. 
Immunoblotting for β-actin was performed to verify equal loading. Representative 
blots of more than three independent experiments are shown (B). 
